Sema7A is crucial for resolution of severe inflammation.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
02 03 2021
Historique:
entrez: 27 2 2021
pubmed: 28 2 2021
medline: 10 8 2021
Statut: ppublish

Résumé

Endogenous mediators regulating acute inflammatory responses in both the induction and resolution phases of inflammatory processes are pivotal in host defense and tissue homeostasis. Recent studies have identified neuronal guidance proteins characterized in axonal development that display immunomodulatory functions. Here, we identify the neuroimmune guidance cue Semaphorin 7A (Sema7A), which appears to link macrophage (MΦ) metabolic remodeling to inflammation resolution. Sema7A orchestrated MΦ chemotaxis and chemokinesis, activated MΦ differentiation and polarization toward the proresolving M2 phenotype, and promoted leukocyte clearance. Peritoneal MΦ

Identifiants

pubmed: 33637648
pii: 2017527118
doi: 10.1073/pnas.2017527118
pmc: PMC7936270
pii:
doi:

Substances chimiques

Antigens, CD 0
Biomarkers 0
Sema7a protein, mouse 0
Semaphorins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Trends Immunol. 2018 Jan;39(1):6-18
pubmed: 28923365
Nat Rev Rheumatol. 2018 Jan;14(1):19-31
pubmed: 29213125
Nat Immunol. 2005 Dec;6(12):1191-7
pubmed: 16369558
Anaesthesiol Intensive Ther. 2017;49(2):83-87
pubmed: 28502071
Hepatology. 2016 May;63(5):1689-705
pubmed: 26573873
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Nat Commun. 2019 Feb 7;10(1):633
pubmed: 30733433
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Cell Death Differ. 2018 Feb;25(2):421-431
pubmed: 29053142
Nat Immunol. 2016 Jan;17(1):9-17
pubmed: 26681457
Cell Metab. 2020 Jan 7;31(1):26-34
pubmed: 31839485
Immunity. 2015 Sep 15;43(3):421-34
pubmed: 26377896
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Cell Death Dis. 2020 Aug 10;11(8):695
pubmed: 32826874
Front Immunol. 2014 Sep 02;5:420
pubmed: 25228902
J Immunol. 2012 Feb 1;188(3):1108-16
pubmed: 22198947
Adv Immunol. 2013;120:163-84
pubmed: 24070384
Immunity. 2014 Mar 20;40(3):315-27
pubmed: 24656045
J Exp Med. 2014 Jun 2;211(6):1037-48
pubmed: 24863066
Nat Rev Immunol. 2019 May;19(5):291-304
pubmed: 30679807
Nature. 2007 Apr 5;446(7136):680-4
pubmed: 17377534
Immunotargets Ther. 2020 Mar 06;9:31-41
pubmed: 32185148
Trends Immunol. 2017 Jun;38(6):444-456
pubmed: 28438491
Nature. 2002 Dec 19-26;420(6917):846-52
pubmed: 12490957
J Clin Invest. 2018 Oct 1;128(10):4711-4726
pubmed: 30222138
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17253-8
pubmed: 24101477
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14146-51
pubmed: 22891341
Eur J Immunol. 2019 Aug;49(8):1153-1166
pubmed: 31016720
Immunity. 2016 Oct 18;45(4):817-830
pubmed: 27760338
Semin Immunol. 2015 Aug;27(4):286-96
pubmed: 26360589
Curr Opin Immunol. 2019 Feb;56:10-16
pubmed: 30240964
Pediatr Crit Care Med. 2016 Jan;17(1):2-9
pubmed: 26492059
Annu Rev Immunol. 2014;32:609-34
pubmed: 24655299
Nat Commun. 2020 Mar 11;11(1):1315
pubmed: 32161256
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
J Exp Med. 2016 Jan 11;213(1):15-23
pubmed: 26694970
Nat Immunol. 2008 Jan;9(1):17-23
pubmed: 18087252
Immunity. 2006 May;24(5):591-600
pubmed: 16713976

Auteurs

Andreas Körner (A)

Department of Anesthesiology and Intensive Care Medicine, Molecular Intensive Care Medicine, University Hospital Eberhard-Karls University, 72076 Tübingen, Germany.

Alice Bernard (A)

Department of Anesthesiology and Intensive Care Medicine, Molecular Intensive Care Medicine, University Hospital Eberhard-Karls University, 72076 Tübingen, Germany.

Julia C Fitzgerald (JC)

Hertie Institute for Clinical Brain Research, University Clinic Tübingen, 72076 Tübingen, Germany.

Juan Carlos Alarcon-Barrera (JC)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.

Sarantos Kostidis (S)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.

Torsten Kaussen (T)

Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Hannover Medical School, 30625 Hannover, Germany.

Martin Giera (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.

Valbona Mirakaj (V)

Department of Anesthesiology and Intensive Care Medicine, Molecular Intensive Care Medicine, University Hospital Eberhard-Karls University, 72076 Tübingen, Germany; valbona.mirakaj@uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH